303 related articles for article (PubMed ID: 6177820)
1. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
Lachmann PJ; Pangburn MK; Oldroyd RG
J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
[TBL] [Abstract][Full Text] [Related]
2. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
3. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
4. Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes.
Lachmann PJ; Voak D; Oldroyd RG; Downie DM; Bevan PC
Vox Sang; 1983; 45(5):367-72. PubMed ID: 6605620
[TBL] [Abstract][Full Text] [Related]
5. Further studies of the C3g component of the alpha 2D fragment of human C3.
Chaplin H; Monroe MC; Lachmann PJ
Clin Exp Immunol; 1983 Mar; 51(3):639-46. PubMed ID: 6602022
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
7. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
[TBL] [Abstract][Full Text] [Related]
8. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
[TBL] [Abstract][Full Text] [Related]
9. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
Medicus RG; Melamed J; Arnaout MA
Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
[TBL] [Abstract][Full Text] [Related]
10. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
Tamerius JD; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
Garred P; Mollnes TE; Lea T; Fischer E
Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
[TBL] [Abstract][Full Text] [Related]
12. The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.
Spitzer RE; Stitzel AE; Pauling VL; Davis NC; West CD
J Exp Med; 1971 Sep; 134(3 Pt 1):656-80. PubMed ID: 15776568
[TBL] [Abstract][Full Text] [Related]
13. Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase.
Carlo JR; Spitznagel JK; Studer EJ; Conrad DH; Ruddy S
Immunology; 1981 Oct; 44(2):381-91. PubMed ID: 7028603
[TBL] [Abstract][Full Text] [Related]
14. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes.
Ross GD; Lambris JD
J Exp Med; 1982 Jan; 155(1):96-110. PubMed ID: 6915077
[TBL] [Abstract][Full Text] [Related]
15. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.
Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Jun; 153(6):1592-603. PubMed ID: 7252421
[TBL] [Abstract][Full Text] [Related]
16. Partial characterization of physiologically generated C3 components expressing C3d but not C3c epitopes.
Siersted HC; Jensenius JC; Svehag SE; Brandslund I
J Clin Lab Immunol; 1983 Dec; 12(4):201-8. PubMed ID: 6198522
[TBL] [Abstract][Full Text] [Related]
17. Interaction of fibronectin with complement component C3.
Hautanen A; Keski-Oja J
Scand J Immunol; 1983 Mar; 17(3):225-30. PubMed ID: 6402811
[TBL] [Abstract][Full Text] [Related]
18. Three rat monoclonal antibodies to human C3.
Lachmann PJ; Oldroyd RG; Milstein C; Wright BW
Immunology; 1980 Nov; 41(3):503-15. PubMed ID: 6161872
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol).
Arnaout MA; Todd RF; Dana N; Melamed J; Schlossman SF; Colten HR
J Clin Invest; 1983 Jul; 72(1):171-9. PubMed ID: 6874946
[TBL] [Abstract][Full Text] [Related]
20. Specificity of three anti-complement factor 3 monoclonal antibodies.
Henwick S; Hetherington SV; Hostetter MK
J Immunol Methods; 1992 Aug; 153(1-2):173-84. PubMed ID: 1517587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
